OCY Stock Overview
An immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Oncimmune Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.12 |
| 52 Week High | UK£0.34 |
| 52 Week Low | UK£0.11 |
| Beta | 1.08 |
| 11 Month Change | -49.13% |
| 3 Month Change | -43.75% |
| 1 Year Change | -27.33% |
| 33 Year Change | -94.06% |
| 5 Year Change | -88.30% |
| Change since IPO | -92.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| OCY | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.8% | -1.8% | -0.1% |
| 1Y | -27.3% | -18.5% | 2.4% |
Return vs Industry: OCY underperformed the German Biotechs industry which returned -18.5% over the past year.
Return vs Market: OCY underperformed the German Market which returned 2.4% over the past year.
Price Volatility
| OCY volatility | |
|---|---|
| OCY Average Weekly Movement | 13.1% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: OCY's share price has been volatile over the past 3 months.
Volatility Over Time: OCY's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Martin Gouldstone | www.oncimmune.com |
Oncimmune Holdings plc, an immunodiagnostics company, develops solutions for immuno-oncology, autoimmune disease and infectious diseases in the United Kingdom, North America, Europe, and internationally. It offers EarlyCDT-Lung, an immunodiagnostic blood test for detecting and identifying lung cancer; ImmunoINSIGHTS that enables life science organizations to optimize drug development and delivery; SeroTag discovery arrays for discovering and validating biomarkers for stratifying patients in multiple cancer indications, infectious diseases, and with various autoimmune diseases; and NavigAID, a disease-specific characterization panel. Oncimmune Holdings plc was incorporated in 2015 and is based in Leeds, the United Kingdom.
Oncimmune Holdings plc Fundamentals Summary
| OCY fundamental statistics | |
|---|---|
| Market cap | €9.76m |
| Earnings (TTM) | -€3.71m |
| Revenue (TTM) | €1.43m |
6.8x
P/S Ratio-2.6x
P/E RatioIs OCY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCY income statement (TTM) | |
|---|---|
| Revenue | UK£1.21m |
| Cost of Revenue | UK£445.00k |
| Gross Profit | UK£769.00k |
| Other Expenses | UK£3.91m |
| Earnings | -UK£3.14m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.042 |
| Gross Margin | 63.34% |
| Net Profit Margin | -258.65% |
| Debt/Equity Ratio | -404.9% |
How did OCY perform over the long term?
See historical performance and comparison